 BAUDETTE, Minn.--BUSINESS WIRE--ANI Pharmaceuticals, Inc. ANI or the Company Nasdaq: ANIP today announced that the Company has re-filed its supplemental new drug application sNDA for Cortrophin Gel with the U.S. Food and Drug Administration FDA. We are delighted to have re-filed our sNDA for Cortrophin Gel in the last week of June. ANI has carefully reviewed every communication from the FDA with our internal subject matter experts and enlisted additional expert advice from i 